Construct: ORF ccsbBroadEn_10962
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF004378.1_s300c1, BRDN0000389973
- DNA Barcode:
- None
- Epitope Tag:
- None
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- MEF2A (4205)
Vector Information:
- Vector Backbone:
- pDONR223
- Pol II Cassette 1:
- n/a
- Pol II Cassette 2:
- n/a
- Selection Marker:
- n/a
- Visible Reporter:
- n/a
- Epitope Tag:
- n/a
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001130928.2 | 97.2% | 97.4% | 1_33del;657T>C;663G>A |
| 2 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521587.2 | 97.2% | 97.4% | 1_33del;657T>C;663G>A |
| 3 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001130927.3 | 95.4% | 95.6% | (many diffs) |
| 4 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365209.1 | 95.4% | 95.6% | (many diffs) |
| 5 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022195.1 | 91.5% | 90.2% | (many diffs) |
| 6 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521585.2 | 89.9% | 87.8% | (many diffs) |
| 7 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022199.1 | 89.3% | 86.5% | (many diffs) |
| 8 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022200.1 | 88.1% | 87.4% | (many diffs) |
| 9 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022201.1 | 88.1% | 87.4% | (many diffs) |
| 10 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022196.1 | 87.6% | 84.9% | (many diffs) |
| 11 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022197.2 | 86.5% | 85.7% | (many diffs) |
| 12 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022198.2 | 86.5% | 85.7% | (many diffs) |
| 13 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022202.1 | 83.8% | 84% | (many diffs) |
| 14 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001130926.2 | 83.8% | 82.8% | (many diffs) |
| 15 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001171894.3 | 83.8% | 82.8% | (many diffs) |
| 16 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352614.2 | 83.8% | 82.8% | (many diffs) |
| 17 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352615.2 | 83.8% | 82.8% | (many diffs) |
| 18 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365208.1 | 83.8% | 82.8% | (many diffs) |
| 19 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001319206.2 | 82.5% | 81.5% | (many diffs) |
| 20 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352616.2 | 82.5% | 81.5% | (many diffs) |
| 21 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365205.1 | 82.5% | 81.5% | (many diffs) |
| 22 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352617.2 | 81.5% | 76.7% | (many diffs) |
| 23 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365207.1 | 81.5% | 76.7% | (many diffs) |
| 24 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_005587.4 | 81.5% | 76.7% | (many diffs) |
| 25 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352618.2 | 80.9% | 76.1% | (many diffs) |
| 26 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365206.1 | 80.9% | 76.1% | (many diffs) |
| 27 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365203.1 | 80.2% | 75.5% | (many diffs) |
| 28 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365204.1 | 80.2% | 75.5% | (many diffs) |
| 29 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521582.2 | 80.2% | 75.5% | (many diffs) |
| 30 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022191.1 | 80.2% | 75.5% | (many diffs) |
| 31 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365201.1 | 79.7% | 74.9% | (many diffs) |
| 32 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365202.1 | 79.7% | 74.9% | (many diffs) |
| 33 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521572.2 | 79.7% | 74.9% | (many diffs) |
| 34 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521573.2 | 79.7% | 74.9% | (many diffs) |
| 35 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521577.2 | 79.7% | 74.9% | (many diffs) |
| 36 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521578.2 | 79.7% | 74.9% | (many diffs) |
| 37 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521579.2 | 79.7% | 74.9% | (many diffs) |
| 38 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521590.2 | 40.9% | 34.7% | (many diffs) |
| 39 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XR_001751289.1 | 38.8% | (many diffs) | |
| 40 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365211.2 | 32.9% | 29.1% | (many diffs) |
| 41 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365210.2 | 31% | 23.2% | (many diffs) |
| 42 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_005254916.3 | 30.8% | 23% | (many diffs) |
| 43 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291196.1 | 75.7% | 80.3% | (many diffs) |
| 44 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291195.1 | 75.3% | 78.4% | (many diffs) |
| 45 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001033713.2 | 74.1% | 77.2% | (many diffs) |
| 46 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_006540686.3 | 74.1% | 77.2% | (many diffs) |
| 47 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_017322011.1 | 74.1% | 77.2% | (many diffs) |
| 48 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291191.1 | 73.2% | 72.3% | (many diffs) |
| 49 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291192.1 | 73.2% | 72.3% | (many diffs) |
| 50 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_011250814.2 | 73.2% | 72.3% | (many diffs) |
| 51 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_006540684.3 | 72% | 71.2% | (many diffs) |
| 52 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_006540685.3 | 72% | 71.2% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 66
- ORF end:
- 1320
- ORF length:
- 1254
- Sequence:
-
1 gttcgttgca acaaattgat gagcaatgct tttttataat gccaaCTTTG TACAAAAAAG 61 TTGGCATGGA TGAAAGGAAC CGACAGACTT TAAGAAAGAA AGGCCTTAAT GGTTGTGAGA 121 GCCCTGATGC TGACGATTAC TTTGAGCACA GTCCACTCTC GGAGGACAGA TTCAGCAAAC 181 TAAATGAAGA TAGTGATTTT ATTTTCAAAC GAGGCCCTCC TGGTCTGCCA CCTCAGAACT 241 TTTCAATGTC TGTCACAGTT CCAGTGACCA GCCCCAATGC TTTGTCCTAC ACTAACCCAG 301 GGAGTTCACT GGTGTCCCCA TCTTTGGCAG CCAGCTCAAC GTTAACAGAT TCAAGCATGC 361 TCTCTCCACC TCAAACCACA TTACATAGAA ATGTGTCTCC TGGAGCTCCT CAGAGACCAC 421 CAAGTACTGG CAATGCAGGT GGGATGTTGA GCACTACAGA CCTCACAGTG CCAAATGGAG 481 CTGGAAGCAG TCCAGTGGGG AATGGATTTG TAAACTCAAG AGCTTCTCCA AATTTGATTG 541 GAGCTACTGG TGCAAATAGC TTAGGCAAAG TCATGCCTAC AAAGTCTCCC CCTCCACCAG 601 GTGGTGGTAA TCTTGGAATG AACAGTAGGA AACCAGATCT TCGAGTTGTC ATCCCCCCTT 661 CAAGCAAGGG CATGATGCCT CCACTAAACA CCCAAAGGAT CAGTAGTTCT CAAGCCACTC 721 AACCTCTTGC TACCCCAGTC GTGTCTGTGA CAACCCCAAG CTTGCCTCCG CAAGGACTTG 781 TGTACTCAGC AATGCCGACT GCCTACAACA CTGATTATTC ACTGACCAGC GCTGACCTGT 841 CAGCCCTTCA AGGCTTCAAC TCGCCAGGAA TGCTGTCGCT GGGACAGGTG TCGGCCTGGC 901 AGCAGCACCA CCTAGGACAA GCAGCCCTCA GCTCTCTTGT TGCTGGAGGG CAGTTATCTC 961 AGGGTTCCAA TTTATCCATT AATACCAACC AAAACATCAG CATCAAGTCC GAACCGATTT 1021 CACCTCCTCG GGATCGTATG ACCCCATCGG GCTTCCAGCA GCAGCAGCAG CAGCAGCAGC 1081 AGCAGCAGCC GCCGCCACCA CCGCAGCCCC AGCCACAACC CCCGCAGCCC CAGCCCCGAC 1141 AGGAAATGGG GCGCTCCCCT GTGGACAGTC TGAGCAGCTC TAGTAGCTCC TATGATGGCA 1201 GTGATCGGGA GGATCCACGG GGCGACTTCC ATTCTCCAAT TGTGCTTGGC CGACCCCCAA 1261 ACACTGAGGA CAGAGAAAGC CCTTCTGTAA AGCGAATGAG GATGGACGCG TGGGTGACCT 1321 ACCCAACTTT CTTGTACAAA GTtggcatta taagaaagca ttgcttatca atttgttgca 1381 acgaac